ArticlePloS one2025
Antitumor and cytotoxic activities of endophytic Enterobacter hormaechei derived secondary metabolites: In-vitro and In-silico study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In silico modeling and in vitro evaluation of antidiabetic potential of exopolysaccharides from Brassicaceae root endophytic bacteria.Journal, genetic engineering & biotechnology · 2026Article
- Endophytic bacteria associated with turmeric, ginger and white radish exhibit dual roles as producers of antibacterial metabolites and carriers of multidrug resistance.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticancer therapies resistance, as well as their existing side effects, has become a significant issue worldwide. The demands of new anticancer agents that prevent cancer from developing and growing or spreading are increasing day by day. In this regard, our investigation assessed the cytotoxic and anticancer properties of secondary metabolites (SMs) obtained from understudied endophytic bacteria inhibiting Alliaria petiolata. The identified SMs were further screened by computational analysis against angiogenic factors of cancer. As a result, the leaf sample-associated isolate was identified as Enterobacter hormaechei AP2 strain. Gas chromatography-mass spectroscopy (GC-MS) analysis has shown the existence of 27 compounds present in the crude extract with main compounds being; 4,4-Ethylenedioxy-1-pentylamine (22.54%), Triethanolamine (15.17%) and 2-isobutoxyethyl acetate (12.51%). The extract showed anticancer activity with IC50 = 145 µM against the human glioblastoma cell line and cytotoxic activity with LC50 = 214.1 μg/mL against Artemia salina nauplii. The metabolite; 3-(2-Methylpropyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione was predictively found most effective by computational analysis against angiogenic factors of cancer. It also demonstrated high intestinal solubility as well as low toxicity. In conclusion, the presence of E. hormaechei within A. petiolata may provide a wealth of bioactive chemicals. Validating the current discovery, purification, its biosynthesis route and other biological functions were recommended for additional research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.